Elekta AB
https://www.elekta.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Elekta AB
News We're Watching: TCT Yields More Encouraging Results For TAVR; HeartPoint Resets Trial Plans, Butterfly Tries Brain-Interface Tech
Clinical trial results announced at the Transcatheter Therapeutics conference in San Francisco headlined the medtech research and development news last week. Noteworthy "commercial" developments in late October include iCad’s decision to sell its Xoft brachytherapy business to Elekta and Butterfly Network's plans to work with Forest Neurotech on brain-computer interfaces.
Asia Deal Watch: Maruho Licenses Rights In Japan To GI Innovation’s Allergy Candidate
Plus deals involving BioLineRx/GloriaBio, Healios/Athersys, Aurobindo/Hilleman, Lupin/Menarini, GC Biopharma/Immetas, CanariaBio, Specialised Therapeutics, TaiGen/Y.S.P., Nippon/Kayaku/Adlai Nortye, WuXi/PharmaEssentia, Evommune/Maruho and Ono/Adimab.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Royal Philips’ IGT Goes For The Structural Heart
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.
Company Information
- Industry
- Services
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Acumyn
- Elekta Instrument AB
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice